Aristotle University Of Thessaloniki (AUTH)
Η προγνωστική και προβλεπτική σημασία της συν-έκφρασης των γονιδίων HER-2 και τοποϊσομεράσης 2Α σε ασθενείς με καρκίνο του μαστού
Abstract
dc:descriptionThe HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel or anthracyclines. The TOP2A gene has been associated with response to anthracyclines. The relationship of HER2/TOP2A gene status in the presence of centromere 17 (CEN17) gain with patient outcome following adjuvant treatment with anthracyclines, with or without paclitaxel, has not been established. Formalin-fixed paraffin-embedded tumor tissue samples from 1031 patients with high-risk operable breast cancer, enrolled in two consecutive phase III trials, were assessed in a central laboratory by fluorescence in situ hybridization for HER2/TOP2A gene amplification and CEN17 gain (CEP17 probe). HER2 and TOP2A amplification was defined as a gene/CEP17 ratio of ≥2.2 and ≥2.0, respectively, or gene copy number of higher than 6. Additionally, HER2, TopoIIa, ER/PgR and Ki67 expression was assessed by immunohistochemistry (IHC) and patients were classified according to their IHC phenotype. Treatment consisted of epirubicin-based adjuvant chemotherapy followed by hormonal therapy and radiation, as indicated. HER2 amplification was found in 23.7% of the patients and TOP2A amplification in 10.1%. In total, 41.8% of HER2-amplified tumors demonstrated TOP2A co-amplification. The median (range) of HER2, TOP2A and CEN17 gain was 2.55 (0.70-45.15), 2.20 (0.70-26.15) and 2.00 (0.70-26.55), respectively. Forty percent of the tumors were found to have CEN17 gene gain (51% of those with HER2 amplification). Adjusting for treatment groups in the Cox model, HER2 amplification, TOP2A amplification, CEN17 gain and HER2/TOP2A co-amplification were not associated with either relapse or death. HER2 amplification, TOP2A amplification, CEN17 gain and HER2/TOP2A co-amplification were not associated with outcome.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Xanthakis, Ioannis
- Ξανθάκης, Ιωάννης
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29093